Moderna Expands the Field of mRNA Medicine with Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced positive clinical results across cancer, rare disease, and infectious disease. The company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial. Moderna, in partnership with Merck, plans to begin a second Phase 3 trial of mRNA-4157 for non-small cell lung cancer. The company also announced positive data in mRNA-3705, a treatment for methylmalonic acidemia. Over the next five years, Moderna expects to launch up to 15 new products and bring up to 50 new candidates into clinical trials.
September 13, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's partnership with Moderna for the Phase 3 trial of mRNA-4157 could potentially have a positive impact on Merck's stock in the short term.
Partnerships for clinical trials can have a positive impact on a company's stock as they indicate potential future revenue streams and growth potential. However, the impact may be less direct for Merck as it is a larger company with a more diverse portfolio.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Moderna's positive clinical results and plans for future product launches and clinical trials could potentially boost the company's stock in the short term.
Positive clinical trial results generally have a positive impact on a biotech company's stock as they indicate potential future revenue streams. Moderna's announcement of future product launches and clinical trials also signals growth potential, which could attract investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100